West Pharmaceutical Services Inc. has taken a significant step forward by expanding its Damastown facility in Dublin. This new addition encompasses 165,000 square feet and aims to boost contract manufacturing capacity for high-volume injectable therapies.
Expansion Details
The newly expanded site will enhance West’s ability to cater to the increasing demand for complex injectable delivery systems. These systems are crucial for treating various health challenges, including diabetes and obesity.
Enhanced Capabilities
- Component molding
- Device assembly
- Advanced packaging
- Automation integration
- Expanded drug-handling operations
Aileen Ruff-Patry, the president of contract manufacturing at West, emphasized the importance of this expansion. She noted that it will provide support for the production of next-generation injectable therapies, including GLP-1 treatments.
Company Overview
West Pharmaceutical Services is headquartered in Exton, Pennsylvania. The company employs over 10,000 individuals across 50 locations globally. In fiscal year 2025, West reported impressive net sales of $3.07 billion.
This expansion underscores West’s commitment to improving drug handling capabilities, reflecting their proactive approach to meet rising market demands. As they enhance their operational capacity, the company remains poised to play a pivotal role in the production of innovative injectable therapies.
